We are exploring new ways to look at liquid biopsy that give us information beyond the standard genetic information that we’re used to obtaining. And these can give us inferences into cell phenotype, including epigenomics and transcriptomic readouts. And so those are really exciting. They’re in their infancy, and we’re still understanding how we can apply them in urothelial cancer...
We are exploring new ways to look at liquid biopsy that give us information beyond the standard genetic information that we’re used to obtaining. And these can give us inferences into cell phenotype, including epigenomics and transcriptomic readouts. And so those are really exciting. They’re in their infancy, and we’re still understanding how we can apply them in urothelial cancer. But I think that in the future, they have potential to give us a lot of biological insight. Who knows where we’ll be in five or ten years and talking about how we can apply these more readily in the clinic. Methylation profiling is something that is being utilized particularly in early cancer detection and so that is potentially one of these sort of non-genetic readouts that we can employ more readily and expect some clinical implementation fairly soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
